AbCellera Biologics (NASDAQ:ABCL – Get Free Report) is expected to be announcing its earnings results after the market closes on Thursday, February 27th. Analysts expect the company to announce earnings of ($0.15) per share and revenue of $7.58 million for the quarter. Investors interested in participating in the company’s conference call can do so using this link.

Shares of NASDAQ ABCL opened at $2.99 on Tuesday. The firm’s 50 day moving average price is $3.09 and its 200-day moving average price is $2.84. AbCellera Biologics has a 52-week low of $2.34 and a 52-week high of $5.26.

Several research analysts have recently issued reports on ABCL shares. Stifel Nicolaus reiterated a “buy” rating and issued a $12.00 target price (down previously from $14.00) on shares of AbCellera Biologics in a research note on Tuesday, November 5th. Benchmark restated a “hold” rating on shares of AbCellera Biologics in a research report on Tuesday, November 5th. Finally, KeyCorp lowered their price objective on shares of AbCellera Biologics from $5.00 to $4.00 and set an “overweight” rating on the stock in a research report on Wednesday, January 8th.

AbCellera Biologics Inc builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company’s preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis.